2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

COM:2SEVENTYBIO

2seventy bio

Last Close

2.55

14/02 21:00

Market Cap

197.91M

Beta: -

Volume Today

153.50K

Avg: -

Filings Not Available